Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,741 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05923008RecruitingPhase 1/Phase 2
Study of IBI130 for advanced solid tumors
This trial tests IBI130 in people with unresectable, locally advanced, or metastatic solid tumors (cancers that can’t be fully removed by surgery or have spread). It may help find whether the drug is safe and can work against these cancers.
Birtinya, QueenslandAges 18 years+ - NCT06151587RecruitingPhase 3
Eye drop to slow myopia in children
This study tests an eye drop (QLM3004) to see if it can slow down the progression of nearsightedness (myopia) in children. It might be a good option if your child is between 6 and 12, has mild to moderate nearsightedness, and hasn't used other myopia treatments before.
Wenzhou, ZhejiangAges 6–12 - NCT06161870RecruitingPhase 4
Individualized vancomycin dosing for NICU patients
This study tests a personalized dosing approach for the antibiotic vancomycin given to patients in the neurological ICU. It aims to find the right dose for each patient to improve treatment and reduce side effects.
Changsha, HunanAges 18 years+ - NCT06001086RecruitingPhase 2
Disitamab Vedotin plus Pyrotinib for HER2-positive early breast cancer
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
Nanjing, JiangsuAges 18 years+ - NCT06197139RecruitingPhase 1
Study of a new targeted radiation therapy for advanced solid tumors
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
GuangzhouAges 18 years+ - NCT06190639RecruitingPhase 2
Sintilimab after surgery for node-positive esophageal cancer
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hangzhou, ZhejiangAges 18 years+ - NCT06205576Recruiting
Balloon treatment for narrowed AV fistula veins
This trial tests a balloon device to open up narrowed veins in an AV fistula used for dialysis. It may help if your fistula has a blockage that causes problems like high pressure or low blood flow.
BeijingAges 18–85 - NCT07865793RecruitingPhase 2
Lattice radiation with immunotherapy for advanced tumors
This trial tests a new way to give radiation called lattice therapy together with immunotherapy drugs that help your immune system fight cancer. It is for people with advanced solid tumors that have grown or spread, with at least one large tumor that can be measured.
Shenzhen, GuangdongAges 18–70 - NCT06211647RecruitingPhase 1
177Lu XT117 for advanced solid tumors
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
BeijingAges 18 years+ - NCT06234137Recruiting
Chemo plus targeted therapy for advanced HER2+ breast cancer
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
Wenzhou, ZhejiangAges 18–75 - NCT06231953Recruiting
Building a multi-cancer early detection test using DNA
This study uses a blood test to look for DNA changes that could signal cancer early. It includes both people with cancer and healthy volunteers to help build a better screening tool.
SeoulAges 19 years+ - NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT06235931Recruiting
Darcilil with AI and pyrrotinib for advanced breast cancer
This trial tests a combination of three drugs (darcilil, an aromatase inhibitor, and pyrrotinib) for older adults with a specific type of advanced breast cancer that has both HER2 and hormone receptors. It aims to see if this mix works better than current treatments.
Suzhou, JiangsuAges 65 years+ - NCT06254690RecruitingPhase 2
Pyrotinib dosing study for HER2-positive advanced breast cancer
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Nanjing, JiangsuAges 18–70 - NCT07856329RecruitingPhase 2/Phase 3
Gene therapy for duchenne muscular dystrophy
This trial tests a gene therapy to help boys with Duchenne muscular dystrophy (DMD) keep their muscle strength. It aims to see if the treatment is safe and effective for young boys who are still walking.
BrusselsAges 6–10 - NCT05970666RecruitingPhase 2
TACE plus immunotherapy and VEGF drug for unresectable liver cancer
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
Xiamen, FujianAges 18–75 - NCT06101082RecruitingPhase 1
Testing anti-HER2-CAR-T cells for advanced solid tumors
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
Shenyang, LiaoningAges 18–70 - NCT06091774Recruiting
Digital therapy for heart disease risk factors
This study tests a smartphone app (iATROS) for managing heart disease risk factors in patients with coronary heart disease. If you have had a heart attack, a stent, angioplasty, or bypass surgery, and you can use a smartphone, this program may help you reduce your risk through digital monitoring and guidance.
Munich, BavariaAges 18 years+ - NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT06328179Recruiting
VHEA treatment for leukemia with KMT2A gene changes
This trial tests a combination treatment (VHEA) for adults with newly diagnosed or relapsed acute myeloid leukemia (AML) that has a specific genetic change called KMT2A. It aims to see if this treatment is safe and effective for patients who meet certain health requirements.
Huai'an, JiangsuAges 18–60 - NCT05514015RecruitingPhase 4
Rituximab with steroids or rituximab alone for membranous kidney disease
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Guangzhou, GuangdongAges 18–75 - NCT02799537Recruiting
Compare a new end-of-life letter to advance directives
This study compares two ways of sharing your end-of-life wishes: a “Stanford Letter Project” form versus traditional advance directives. If you’re an adult, your answers may help the researchers see which option is easier to use or better understood.
Stanford, CaliforniaAges 18 years+ - NCT06349629Recruiting
Testing a new dissolving metal implant for joint fractures
This trial tests a new 3D-printed metal implant made of a special magnesium alloy that dissolves over time. It is designed to help mend broken bones near joints, such as wrist, shoulder, or knee fractures, where there is a missing piece of bone.
Beijing, HaidianAges 18–80 - NCT06252298RecruitingPhase 1
Testing a new drug for CD38-positive blood cancers
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,741 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.